November 30, 2023 Sandra Stoneman Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Sandra:Immunome Inc. • March 28th, 2024 • Pharmaceutical preparations
On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Chief Legal Officer of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment should you accept the offer. This letter agreement, if accepted by you, will be effective as of November 1, 2023 (the “Effective Date”). Certain capitalized terms are defined in Section 11 below.
October 2, 2023 By Hand and Email Dennis Giesing dhgiesing@gmail.com Re:Separation Agreement Dear Dennis:Letter Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations
This letter agreement (“Agreement”) sets forth the agreement concerning the end of your employment with Immunome, Inc. (the “Company”). Payment and provision of the Severance Benefits (defined below) is contingent on your agreement to and compliance with the terms of this Agreement. Terms not defined herein shall have the meaning set forth in the employment offer letter dated March 4, 2021 (the “Employment Agreement”), as applicable.
AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations • Washington
This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of December 1, 2023 (the “Effective Date”) by and between Immunome, Inc., a Delaware corporation (the “Company”), and Clay B. Siegall, Ph.D., an individual resident in the State of Washington (the “Executive”) (the Company and the Executive are hereinafter sometimes individually referred to as a “Party” and together referred to as the “Parties”).
April 26, 2021 Robert Lapetina Collegeville, PA 19426 Dear Bob,Immunome Inc. • March 28th, 2024 • Pharmaceutical preparations
On behalf of Immunome, Inc. (the “Company”), I am pleased to make this conditional offer of employment to you as our Controller. The purpose of this letter agreement is to set forth the terms of the offer and your employment should you accept the offer.
IMMUNOME, INC. CONSULTING AGREEMENTConsulting Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations • Pennsylvania
CONSULTING AGREEMENT effective as of October 2, 2023 (the “Effective Date”) between Immunome, Inc., a Delaware corporation (the “Company”), and the undersigned consultant to the Company (the “Consultant”).
ASSET PURCHASE AGREEMENT by and between Atreca, Inc. and Immunome, Inc. Dated as of December 22, 2023Asset Purchase Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is made and executed as of December 22, 2023 (the “Execution Date”), by and between ATRECA, INC., a Delaware corporation (“Seller”) and Immunome, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
October 3, 2023 By Hand and Email Purnanand Sarma sarmap97@gmail.com Re:Separation Agreement Dear Sarma:Separation Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations
This letter agreement (“Agreement”) sets forth the agreement concerning the end of your employment with Immunome, Inc. (the “Company”). Payment and provision of the Severance Benefits (defined below) is contingent on your agreement to and compliance with the terms of this Agreement. Terms not defined herein shall have the meaning set forth in the Amended and Restated Employment Agreement between you and the Company effective as of October 14, 2020 (the “Employment Agreement”), as applicable.
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ZENTALIS...License Agreement • March 28th, 2024 • Immunome Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of January 5, 2024 (the “Effective Date”) by and between ZENTALIS PHARMACEUTICALS, INC., a Delaware corporation with an office at 1359 Broadway, Suite 801, New York, New York 10018, U.S. (“Licensor”), and IMMUNOME, INC., a Delaware corporation with an office at 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341, U.S. (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
